Plasma pTau181/Aβ42 identifies cognitive change earlier than CSF pTau181/Ab42. (20th December 2022)

• Record Type: Journal Article
• Authors: Fowler, Christopher; Stoops, Erik; Rainey‐Smith, Stephanie; Vanmechelen, Eugeen; Vanbrabant, Jeroen; Dewit, Nele; Mauroo, Kimberley; Rowe, Christopher; Fripp, Jurgen; Li, Qiao‐Xin; Bourgeat, Pierrick; Collins, Steven; Martins, Ralph N; Masters, Colin L; Maruff, Paul; Doecke, James D
• Is Part Of: Alzheimer's & dementia. Volume 18(2022)Supplement 6
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-20
• Subjects: Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.064341
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Background: Plasma biomarkers now show an accuracy in detecting Amyloid Beta (Aβ) similar to AD biomarkers derived from cerebral spinal fluid (CSF). However, the ability of plasma AD biomarkers, alone or in combination, to predict cognitive decline has not yet been compared to that of CSF AD biomarkers. Method: Plasma biomarker data from 233 participants' first visit in the Australian Imaging, Biomarkers and Lifestyle study (AIBL) was submitted to linear mixed effects models (LME) to quantify the relationship with change in cognition (measured using the AIBL PACC) and in clinical disease stage (CDR SoB) in both PET Aβ‐ (Centiloid value <20CL) and Aβ+ (Centiloid value ≥20CL) participant subgroups. Separate models were used to assess CSF (Elecsys) and plasma (ADx NeuroSciences) data for Aβ42, pTau181 and the pTau181/Aβ42 ratio. Biomarker values were classified into low vs high levels based on ROC‐derived thresholds optimizing separation of PET Aβ status (low vs high at 20 CL). Changes in cognitive and clinical symptoms were then compared between the low/high plasma biomarker groups. Result: In Aβ‐ participants, no significant interactions between binary biomarker classification and time were observed for AIBL PACC or CDR SoB, for either CSF or plasma biomarkers. In the Aβ+ participants, interactions between the binary plasma biomarker classification and change in cognition were greater in magnitude that those detected for CSF biomarker classification. For plasma, abnormally high values of both pTau181 and the pTau181/Aβ42 ratio predicted a significant increase over time in CDR SoB (Figure 1H & 1L) and a significant decrease over time in the AIBL PACC score (Figure 1F & 1J), compared the group with low values on the same biomarkers. In cognitively unimpaired Aβ‐ participants, the AIBL PACC score declined in those with abnormally high values of the pTau181 and the pTau181/Aβ42 ratio (Figure 1F & 1J). Conclusion: Assays to measure pTau181 and Aβ42 in the plasma possess an accuracy equivalent to those derived from CSF. In particular, abnormally high levels of plasma pTau181 or the ratio of pTau181 to Aβ42 ratio provide a strong prediction of early cognitive changes, even in those with normal PET Aβ status.